Anktiva Approved for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer – Renal and Urology News
Nogapendekin alfa inbackicept-pmin is an interleukin-15 receptor agonist.
Nogapendekin alfa inbackicept-pmin is an interleukin-15 receptor agonist.
There was a statistically significant reduction in average daily micturition episodes and average daily urgency episodes with vibegron vs placebo.
“What we need is continued work on integrating surgery and systemic therapy,” says Patrick Kenney, MD.
The EAU Non-neurogenic Female Luts Guidelines aim to provide an overview of the aspects relating to non-neurogenic female LUTS in adult females.
Attaining a tetrafecta composite outcome during radical nephroureterectomy (RNU) does not decrease the risk of cancer recurrence or increase overall
Zach Klaassen and Hanan Goldberg discuss the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC), highlighting the impact of PSMA PET scans on diminishing this…
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.
The American Urological Association (AUA) published the white paper, Catheter-Associated Urinary Tract Infections: Definitions and Significance in the Urologic Patient, in 2014. At that time,…
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Read our Cookies
AUA 2024, bladder cancer, Blue Light Cystoscopy, White Light Cystoscopy, Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern…